You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-680-ESGO Safety and efficacy of MORAb-202 in patients with platinum-resistant ovarian cancer: results from the expansion part of a phase 1 trial in Japan

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-680-ESGO Safety and efficacy of MORAb-202 in patients with platinum-resistant ovarian cancer: results from the expansion part of a phase 1 trial in Japan
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Nishio S, Yunokawa M, Matsumoto K, et al
2022-RA-680-ESGO Safety and efficacy of MORAb-202 in patients with platinum-resistant ovarian cancer: results from the expansion part of a phase 1 trial in Japan
International Journal of Gynecologic Cancer 2022;32:A253-A254.